Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN): Price and Financial Metrics
BHVN Price/Volume Stats
| Current price | $42.16 | 52-week high | $62.21 |
| Prev. close | $44.03 | 52-week low | $12.35 |
| Day low | $41.00 | Volume | 3,668,400 |
| Day high | $43.31 | Avg. volume | 1,216,560 |
| 50-day MA | $51.83 | Dividend yield | N/A |
| 200-day MA | $34.81 | Market Cap | 3.44B |
BHVN Stock Price Chart Interactive Chart >
Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN) Company Bio
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. The company was founded in 2013 and is based in New Haven, Connecticut.
Latest BHVN News From Around the Web
Below are the latest news stories about BIOHAVEN LTD that investors may wish to consider to help them evaluate BHVN as an investment opportunity.
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual MeetingBiohaven Ltd. (NYSE: BHVN) announced today that it is presenting expanded EEG and safety data for BHV-7000 at the 2023 American Epilepsy Society (AES) Annual Meeting, taking place December 1-5, 2023, in Orlando, Florida. The presentations include results from the BHV-7000 Phase 1 EEG biomarker study and additional BHV-7000 safety and tolerability data from Phase 1 single ascending dose (SAD) / multiple ascending dose (MAD) studies. Additional posters showcase BHV-7000's preclinical data, finding |
Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Biohaven... |
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year. |
Biohaven Ltd (BHVN) Reports Q3 2023 Financial Results: Advances in Clinical Programs and Strong ...Key Developments Include Progress in Immunology and CNS Programs, Enhanced by Successful Public Offering |
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business DevelopmentsBiohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones. |
BHVN Price Returns
| 1-mo | -28.98% |
| 3-mo | -4.94% |
| 6-mo | 54.04% |
| 1-year | 199.01% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -1.50% |
| 2023 | 208.36% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...